Cimoxatone
Cimoxatone is a monoamine oxidase inhibitor (MAOI) that was developed in the 1970s for the treatment of depression. It was never marketed, but has been used in scientific research.
Pharmacology[edit]
Cimoxatone acts by inhibiting the action of the enzyme monoamine oxidase, specifically MAO-A. This enzyme is responsible for breaking down monoamine neurotransmitters in the brain, including serotonin, norepinephrine, and dopamine. By inhibiting this enzyme, Cimoxatone increases the levels of these neurotransmitters in the brain, which can help to alleviate the symptoms of depression.
History[edit]
Cimoxatone was developed in the 1970s by the pharmaceutical company Upjohn. It was one of a number of MAOIs developed during this period, as part of a search for safer and more effective treatments for depression. However, Cimoxatone was never marketed, possibly due to concerns about the safety of MAOIs.
Research[edit]
Despite never being marketed, Cimoxatone has been used in scientific research. It has been used as a tool to study the role of monoamine oxidase in the brain, and the effects of its inhibition. It has also been used in studies of depression and other psychiatric disorders.
See also[edit]
References[edit]
